PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35062998-0	2022	Correction to: ARNTL hypermethylation promotes tumorigenesis and inhibits cisplatin sensitivity by activating CDK5 transcription in nasopharyngeal carcinoma.	Cisplatin	74-83	cyclin dependent kinase 5	Homo sapiens	110-114	
26698249-0	2015	Cyclin I promotes cisplatin resistance via Cdk5 activation in cervical cancer.	Cisplatin	18-27	cyclin dependent kinase 5	Homo sapiens	43-47	
26698249-11	2015	The further mechanism investigated showed that cyclin I upregulated the expression of cyclin-dependent kinase 5 (Cdk5) promoting cisplatin resistance by preventing apoptosis in CC cell line.	Cisplatin	129-138	cyclin dependent kinase 5	Homo sapiens	86-111	
26698249-11	2015	The further mechanism investigated showed that cyclin I upregulated the expression of cyclin-dependent kinase 5 (Cdk5) promoting cisplatin resistance by preventing apoptosis in CC cell line.	Cisplatin	129-138	cyclin dependent kinase 5	Homo sapiens	113-117	
26698249-12	2015	Consistently, the cyclin I overexpressed Hela cell lines produce increased sensitivity to cisplatin treatment through knockdown of Cdk5 protein with siRNA.	Cisplatin	90-99	cyclin dependent kinase 5	Homo sapiens	131-135	
26698249-13	2015	CONCLUSIONS: These data suggest that a cyclin I-Cdk5 complex forms a critical antiapoptotic factor in the process of generating cisplatin resistance in cervical cancer.	Cisplatin	128-137	cyclin dependent kinase 5	Homo sapiens	48-52	
30621723-14	2019	CONCLUSIONS: ARNTL suppresses NPC cell proliferation and enhances sensitivity to cisplatin by targeting CDK5.	Cisplatin	81-90	cyclin dependent kinase 5	Homo sapiens	104-108	
29996940-15	2018	Hence, the inhibition of this signaling using a CDK5 inhibitor exerts a synergistic effect with cisplatin prompting on the design of new therapeutic strategies to inhibit growth of EOC cells.	Cisplatin	96-105	cyclin dependent kinase 5	Homo sapiens	48-52